Inspire Medical Systems (NYSE:INSP) Issues FY 2026 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 1.200-1.400 for the period, compared to the consensus earnings per share estimate of 1.250. The company issued revenue guidance of $850.0 million-$860.0 million, compared to the consensus revenue estimate of $853.6 million.

Analyst Ratings Changes

INSP has been the subject of a number of recent research reports. Wells Fargo & Company set a $69.00 price target on shares of Inspire Medical Systems in a research report on Tuesday. KeyCorp restated a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Oppenheimer raised shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 target price for the company in a research note on Tuesday, August 4th. JPMorgan Chase & Co. raised their target price on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Finally, Zacks Research lowered shares of Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $71.12.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $61.05 on Tuesday. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 13.14, a price-to-earnings-growth ratio of 5.37 and a beta of 0.73. Inspire Medical Systems has a one year low of $38.91 and a one year high of $147.03. The company’s 50-day moving average is $68.69 and its 200 day moving average is $58.82.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, November 2nd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. The business had revenue of $206.69 million during the quarter, compared to analysts’ expectations of $204.31 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business’s revenue for the quarter was down 7.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.38 earnings per share. As a group, research analysts predict that Inspire Medical Systems will post 1.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider directly owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.20% of the stock is currently owned by insiders.

Key Stories Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire reported third-quarter adjusted EPS of $0.14, ahead of the $0.09 consensus estimate, while revenue of approximately $206.7 million exceeded expectations of $204.3 million. Inspire Medical Systems Announces Third Quarter 2026 Financial Results
• Positive Sentiment: The company’s fiscal 2026 guidance has a midpoint of $1.30 for EPS and $855 million for revenue, modestly above consensus estimates of $1.25 and $853.6 million, respectively. This suggests execution is holding up despite reimbursement-related pressure.
• Positive Sentiment: Robert W. Baird raised its price target from $73 to $77, and Piper Sandler lifted its target from $60 to $70. Both firms retained neutral ratings, indicating improved valuation expectations but limited conviction in a stronger near-term recovery.
• Neutral Sentiment: Management said reimbursement and coding conditions are stabilizing and projected low-single-digit revenue growth for 2027. Stabilization reduces a major business risk, but the expected growth rate remains modest.
• Negative Sentiment: Third-quarter revenue declined 7.9% from the prior year, and EPS fell from $0.38 to $0.14. The results beat reduced expectations but still reflect weaker underlying growth and profitability.
• Negative Sentiment: The neutral analyst ratings and low-single-digit 2027 growth forecast may limit enthusiasm, particularly after Inspire’s shares have already rebounded substantially from their 52-week low.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.